Aldurazyme complete response
Executive Summary
Biomarin's Aldurazyme (laronidase) receives a complete response letter Jan. 28. FDA asked for more information on "postmarketing commitments, final product labeling, and completion of the manufacturing inspections process," Biomarin said. FDA completed its pre-approval inspections, and no further inspections are scheduled. The company expects Aldurazyme's postmarketing commitments to follow the Endocrinologic & Metabolic Drugs Advisory Committee recommendations of antibody formation monitoring. The committee unanimously recommended FDA approve Aldurazyme as treatment for mucopolysaccharidosis I (1"The Pink Sheet" Jan. 20, p. 18)...
You may also be interested in...
Aldurazyme Should Be Indicated For Symptomatic MPS I, Cmte. Says
BioMarin/Genzyme's Aldurazyme should be indicated for symptomatic treatment of mucopolysaccharidosis I, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Jan. 15
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.